Prolight Diagnostics AB (publ)
PRLD.NGM is a company in the Healthcare Equipment industry, specializing in the development and provision of advanced medical equipment and technology.
Business. PRLD.NGM operates in the Health Care sector, specifically within the Biotechnology & Life-Science Tools industry. The company generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the business is described at the industry level without geographic or segment breakdowns.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PRLD.NGM operates in the Health Care sector, specifically within the Biotechnology & Life-Science Tools industry. The company generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the business is described at the industry level without geographic or segment breakdowns.
PRLD.NGM has a strong liquidity position, as evidenced by a current ratio of 2.4, indicating that the company has more than twice the current assets to cover its current liabilities. The company's cash and equivalents amount to 40,606,000 SEK, which is a significant portion of its total assets of 193,431,000 SEK. Despite this, the company reported a negative operating cash flow of -37,005,000 SEK and a free cash flow of -67,574,000 SEK, suggesting that it is currently spending more cash than it is generating.
In terms of profitability, PRLD.NGM reported a gross profit of 15,349,000 SEK but an operating loss of -53,249,000 SEK and a net loss of -49,708,000 SEK. The return on equity (ROE) is -0.2935, and the return on assets (ROA) is -0.257, both of which are negative, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are below the industry median for profitability metrics, suggesting that the company is underperforming its peers in the Healthcare Equipment industry.
PRLD.NGM's revenue is reported as 0.0 SEK, which indicates that the company is not currently generating revenue from its operations. There is no information provided on the company's segments or geographic exposure, so it is not possible to determine the concentration of revenue or the geographic regions in which the company operates.
The company's growth trajectory is unclear due to the lack of revenue data and the absence of a revenue history. The negative operating and net income figures suggest that the company is not in a growth phase and may be facing operational challenges. There is no information provided on the company's outlook for the current or next fiscal year, so it is not possible to determine the direction of its growth.
PRLD.NGM's risk assessment indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and there is no indication of dilution potential based on the number of shares outstanding. The company's debt-to-equity ratio is 0.0, which suggests that it is not leveraging debt to finance its operations. However, the negative operating and free cash flows indicate that the company may face liquidity challenges in the future.
There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The lack of revenue and the negative financial figures suggest that the company may be in a period of transition or facing operational difficulties.
- PRLD.NGM has a strong liquidity position with a current ratio of 2.4 and significant cash and equivalents.
- The company is currently not generating revenue and is reporting a net loss, indicating poor profitability.
- The negative return on equity and return on assets suggest that the company is not effectively utilizing its assets or generating returns for shareholders.
- There is no immediate liquidity or dilution risk, but the negative cash flows may pose future challenges.
- The company's growth trajectory is unclear due to the lack of revenue data and the absence of a revenue history.
- margin_outlook_rationale: The company's margin outlook is negative due to the reported net loss and negative operating income.
- rd_outlook_rationale: There is no information provided on the company's research and development outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, 10% owner · Non-Qualified Stock Option (right to buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Director, 10% owner · Director Stock Option (Right to Buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 38 000 @ $3,94grant · 2026-06-09
- Chief Medical Officer · Employee Stock Option (right to buy) → Common StockAcquired 450 000 @ $4,70grant · 2026-05-01
- 10% owner · Pre-Funded Warrants (Right to Buy) → Common StockAcquired 1 407 000 @ $0,00other · 2026-04-27
- Director, 10% owner · Warrants to purchase Common Stock → Common StockAcquired 2 137 651 @ $0,00purchase · 2026-04-21
- Director, 10% owner · Warrants to purchase Common Stock → Common StockAcquired 114 601 @ $0,00purchase · 2026-04-21
- Chief Chemistry Officer · Employee Stock Option (right to buy) → Common StockAcquired 230 000 @ $2,30grant · 2026-02-04
- Chief Scientific Officer · Employee Stock Option (right to buy) → Common StockAcquired 230 000 @ $2,30grant · 2026-02-04
- CLO, CFO, Corp Sec. · Employee Stock Option (right to buy) → Common StockAcquired 275 000 @ $2,30grant · 2026-02-04
- Director, CEO · Employee Stock Option (right to buy) → Common StockAcquired 837 000 @ $2,30grant · 2026-02-04
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 121 285 @ $1,39grant · 2025-11-05
- Director · Director Stock Option (Right to Buy) → Common StockAcquired 76 000 @ $1,19grant · 2025-10-17
- President, CMO · Restricted Stock Unit → Common StockDisposed 9 375exercise · 2025-10-04
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- PRLD.NGM Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- 10% owner · Common StockOther 1 407 000 · 2026-04-27
- Director, 10% owner · Common StockBought 1 689 189 @ $4,44$7,5M · 2026-04-21
- Director, 10% owner · Common StockBought 1 126 126 @ $4,44$5,0M · 2026-04-21
- Director, 10% owner · Common StockBought 1 689 189 @ $4,44$7,5M · 2026-04-21
- Director, 10% owner · Common StockBought 1 126 126 @ $4,44$5,0M · 2026-04-21
- President, CMO · Common StockOther 9 375 · 2025-10-04
- President, CMO · Common StockOther 3 355 @ $1,47$5K · 2025-10-04
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -145.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -70.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 23.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 23.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 65.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -19.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -47.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -20.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 25.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 45.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 21.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 182.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -91.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.06xDerived (calculated)
- Current ratio (FY 2025-12-31): 1.99xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 73.4%Derived (calculated)
- Net margin (FY 2025-12-31): -819.6%Derived (calculated)
- Cash & equivalents (annual): USD 35.26MSEC XBRL filing
- Operating income (annual): USD -104.57MSEC XBRL filing
- Capex (annual): USD 67KSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Revenue (annual): USD 12.14MSEC XBRL filing
- Net income (annual): USD -99.5MSEC XBRL filing
- Total operating expenses (annual): USD 116.71MSEC XBRL filing